View ValuationEuKedos 将来の成長Future 基準チェック /06現在、 EuKedosの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare 収益成長17.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 09Full year 2025 earnings released: €0.033 loss per share (vs €0.023 loss in FY 2024)Full year 2025 results: €0.033 loss per share (further deteriorated from €0.023 loss in FY 2024). Revenue: €52.9m (up 2.4% from FY 2024). Net loss: €749.0k (loss widened 43% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.New Risk • Mar 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Market cap is less than US$100m (€13.3m market cap, or US$15.4m).分析記事 • Oct 22Sentiment Still Eluding EuKedos S.p.A. (BIT:EUK)EuKedos S.p.A.'s ( BIT:EUK ) price-to-sales (or "P/S") ratio of 0.3x may look like a pretty appealing investment...分析記事 • Jul 11Potential Upside For EuKedos S.p.A. (BIT:EUK) Not Without RiskWhen you see that almost half of the companies in the Healthcare industry in Italy have price-to-sales ratios (or...Reported Earnings • May 05Full year 2024 earnings released: €0.023 loss per share (vs €0.024 profit in FY 2023)Full year 2024 results: €0.023 loss per share (down from €0.024 profit in FY 2023). Revenue: €51.7m (up 4.5% from FY 2023). Net loss: €524.0k (down 194% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€17.1m market cap, or US$19.2m).お知らせ • Apr 10EuKedos S.p.A., Annual General Meeting, Jun 30, 2025EuKedos S.p.A., Annual General Meeting, Jun 30, 2025, at 11:00 W. Europe Standard Time.New Risk • Feb 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (€18.2m market cap, or US$18.8m).Reported Earnings • Apr 07Full year 2023 earnings released: EPS: €0.024 (vs €0.019 in FY 2022)Full year 2023 results: EPS: €0.024 (up from €0.019 in FY 2022). Revenue: €49.5m (up 5.1% from FY 2022). Net income: €556.0k (up 26% from FY 2022). Profit margin: 1.1% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.分析記事 • Mar 15The Returns At EuKedos (BIT:EUK) Aren't GrowingIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...分析記事 • Oct 14EuKedos (BIT:EUK) Seems To Be Using A Lot Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Oct 05New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.8% net profit margin). Market cap is less than US$100m (€20.5m market cap, or US$21.5m).New Risk • Oct 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.8% Last year net profit margin: 1.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.8% net profit margin). Market cap is less than US$100m (€21.5m market cap, or US$22.7m).New Risk • Sep 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€21.9m market cap, or US$23.3m).New Risk • Sep 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€22.7m market cap, or US$24.3m).分析記事 • Aug 10EuKedos (BIT:EUK) Is Doing The Right Things To Multiply Its Share PriceDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Luca Golfieri was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Sep 30First half 2022 earnings released: €0.011 loss per share (vs €0.014 loss in 1H 2021)First half 2022 results: €0.011 loss per share (improved from €0.014 loss in 1H 2021). Revenue: €22.5m (up 2.6% from 1H 2021). Net loss: €257.0k (loss narrowed 19% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 03Is EuKedos (BIT:EUK) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Pierluigi Rosa was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.32, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 23x in the Healthcare industry in Italy. Total returns to shareholders of 32% over the past three years.Reported Earnings • Mar 14Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: €0.025 (up from €0.084 loss in FY 2020). Revenue: €44.0m (down 6.4% from FY 2020). Net income: €570.0k (up €2.49m from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 163%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.分析記事 • Mar 07Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of ReturnThere are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...Reported Earnings • Feb 12Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: €0.025 (up from €0.084 loss in FY 2020). Revenue: €45.2m (down 3.9% from FY 2020). Net income: €570.0k (up €2.49m from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 163%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.分析記事 • Oct 30EuKedos (BIT:EUK) Seems To Be Using A Lot Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Oct 03First half 2021 earnings released: €0.014 loss per share (vs €0.056 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: €21.9m (down 9.4% from 1H 2020). Net loss: €319.0k (loss narrowed 75% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.分析記事 • Sep 04Some Investors May Be Worried About EuKedos' (BIT:EUK) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...分析記事 • May 06Here's Why EuKedos (BIT:EUK) Is Weighed Down By Its Debt LoadDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • May 05Full year 2020 earnings released: €0.084 loss per share (vs €0.023 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €47.0m (down 12% from FY 2019). Net loss: €1.92m (down 473% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 22Would EuKedos S.p.A. (BIT:EUK) Be Valuable To Income Investors?Could EuKedos S.p.A. ( BIT:EUK ) be an attractive dividend share to own for the long haul? Investors are often drawn to...Is New 90 Day High Low • Jan 08New 90-day high: €1.19The company is up 43% from its price of €0.83 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: €1.04The company is up 25% from its price of €0.83 on 15 September 2020. The Italian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period.分析記事 • Dec 07Our Take On EuKedos' (BIT:EUK) CEO SalaryCarlo Iuculano has been the CEO of EuKedos S.p.A. ( BIT:EUK ) since 2013, and this article will examine the executive's...Is New 90 Day High Low • Nov 25New 90-day high: €0.94The company is up 8.0% from its price of €0.87 on 26 August 2020. The Italian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 22% over the same period.Is New 90 Day High Low • Nov 03New 90-day high: €0.90The company is up 10.0% from its price of €0.82 on 05 August 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 11% over the same period.Reported Earnings • Sep 28First half earnings releasedOver the last 12 months the company has reported total losses of €827.0k, with earnings decreasing by €1.35m from the prior year. Total revenue was €51.2m over the last 12 months, down 1.9% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、EuKedos は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BIT:EUK - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202553-106N/A9/30/202553-1-76N/A6/30/202553-1-156N/A3/31/202552-1-148N/A12/31/202452-1-1310N/A9/30/2024510N/AN/AN/A6/30/2024511311N/A3/31/2024501311N/A12/31/2023491410N/A9/30/2023490N/AN/AN/A6/30/2023480410N/A3/31/202348037N/A12/31/202247015N/A9/30/202247156N/A6/30/202247186N/A3/31/202246176N/A12/31/202145156N/A9/30/202144004N/A6/30/202144-1-53N/A3/31/202145-1-25N/A12/31/202047-217N/A9/30/202049-137N/A6/30/202051-158N/A3/31/202052047N/A12/31/201953136N/A9/30/2019531N/A6N/A6/30/2019521N/A5N/A3/31/2019521N/A5N/A12/31/2018521N/A5N/A9/30/2018510N/A5N/A6/30/201851-2N/A6N/A3/31/201851-2N/A5N/A12/31/201751-2N/A4N/A9/30/201750-1N/AN/AN/A6/30/2017500N/A5N/A3/31/2017500N/A5N/A12/31/2016490N/A5N/A9/30/201652-1N/AN/AN/A6/30/201655-1N/A0N/A3/31/201657-1N/A0N/A12/31/201559-1N/A-1N/A9/30/201557-1N/AN/AN/A6/30/201554-1N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: EUKの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: EUKの収益がItalian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: EUKの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: EUKの収益がItalian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: EUKの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EUKの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 12:42終値2026/05/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EuKedos S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Micaela FerrutaIntermonte SIM S.p.A.Kevin TempestiniKT & Partners Srl
Reported Earnings • Apr 09Full year 2025 earnings released: €0.033 loss per share (vs €0.023 loss in FY 2024)Full year 2025 results: €0.033 loss per share (further deteriorated from €0.023 loss in FY 2024). Revenue: €52.9m (up 2.4% from FY 2024). Net loss: €749.0k (loss widened 43% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
New Risk • Mar 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Market cap is less than US$100m (€13.3m market cap, or US$15.4m).
分析記事 • Oct 22Sentiment Still Eluding EuKedos S.p.A. (BIT:EUK)EuKedos S.p.A.'s ( BIT:EUK ) price-to-sales (or "P/S") ratio of 0.3x may look like a pretty appealing investment...
分析記事 • Jul 11Potential Upside For EuKedos S.p.A. (BIT:EUK) Not Without RiskWhen you see that almost half of the companies in the Healthcare industry in Italy have price-to-sales ratios (or...
Reported Earnings • May 05Full year 2024 earnings released: €0.023 loss per share (vs €0.024 profit in FY 2023)Full year 2024 results: €0.023 loss per share (down from €0.024 profit in FY 2023). Revenue: €51.7m (up 4.5% from FY 2023). Net loss: €524.0k (down 194% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€17.1m market cap, or US$19.2m).
お知らせ • Apr 10EuKedos S.p.A., Annual General Meeting, Jun 30, 2025EuKedos S.p.A., Annual General Meeting, Jun 30, 2025, at 11:00 W. Europe Standard Time.
New Risk • Feb 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (€18.2m market cap, or US$18.8m).
Reported Earnings • Apr 07Full year 2023 earnings released: EPS: €0.024 (vs €0.019 in FY 2022)Full year 2023 results: EPS: €0.024 (up from €0.019 in FY 2022). Revenue: €49.5m (up 5.1% from FY 2022). Net income: €556.0k (up 26% from FY 2022). Profit margin: 1.1% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
分析記事 • Mar 15The Returns At EuKedos (BIT:EUK) Aren't GrowingIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
分析記事 • Oct 14EuKedos (BIT:EUK) Seems To Be Using A Lot Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Oct 05New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.8% net profit margin). Market cap is less than US$100m (€20.5m market cap, or US$21.5m).
New Risk • Oct 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.8% Last year net profit margin: 1.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.8% net profit margin). Market cap is less than US$100m (€21.5m market cap, or US$22.7m).
New Risk • Sep 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€21.9m market cap, or US$23.3m).
New Risk • Sep 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€22.7m market cap, or US$24.3m).
分析記事 • Aug 10EuKedos (BIT:EUK) Is Doing The Right Things To Multiply Its Share PriceDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Luca Golfieri was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Sep 30First half 2022 earnings released: €0.011 loss per share (vs €0.014 loss in 1H 2021)First half 2022 results: €0.011 loss per share (improved from €0.014 loss in 1H 2021). Revenue: €22.5m (up 2.6% from 1H 2021). Net loss: €257.0k (loss narrowed 19% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 03Is EuKedos (BIT:EUK) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Pierluigi Rosa was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.32, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 23x in the Healthcare industry in Italy. Total returns to shareholders of 32% over the past three years.
Reported Earnings • Mar 14Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: €0.025 (up from €0.084 loss in FY 2020). Revenue: €44.0m (down 6.4% from FY 2020). Net income: €570.0k (up €2.49m from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 163%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 07Here's What To Make Of EuKedos' (BIT:EUK) Decelerating Rates Of ReturnThere are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...
Reported Earnings • Feb 12Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: €0.025 (up from €0.084 loss in FY 2020). Revenue: €45.2m (down 3.9% from FY 2020). Net income: €570.0k (up €2.49m from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 163%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
分析記事 • Oct 30EuKedos (BIT:EUK) Seems To Be Using A Lot Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Oct 03First half 2021 earnings released: €0.014 loss per share (vs €0.056 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: €21.9m (down 9.4% from 1H 2020). Net loss: €319.0k (loss narrowed 75% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
分析記事 • Sep 04Some Investors May Be Worried About EuKedos' (BIT:EUK) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
分析記事 • May 06Here's Why EuKedos (BIT:EUK) Is Weighed Down By Its Debt LoadDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • May 05Full year 2020 earnings released: €0.084 loss per share (vs €0.023 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €47.0m (down 12% from FY 2019). Net loss: €1.92m (down 473% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 22Would EuKedos S.p.A. (BIT:EUK) Be Valuable To Income Investors?Could EuKedos S.p.A. ( BIT:EUK ) be an attractive dividend share to own for the long haul? Investors are often drawn to...
Is New 90 Day High Low • Jan 08New 90-day high: €1.19The company is up 43% from its price of €0.83 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: €1.04The company is up 25% from its price of €0.83 on 15 September 2020. The Italian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period.
分析記事 • Dec 07Our Take On EuKedos' (BIT:EUK) CEO SalaryCarlo Iuculano has been the CEO of EuKedos S.p.A. ( BIT:EUK ) since 2013, and this article will examine the executive's...
Is New 90 Day High Low • Nov 25New 90-day high: €0.94The company is up 8.0% from its price of €0.87 on 26 August 2020. The Italian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 22% over the same period.
Is New 90 Day High Low • Nov 03New 90-day high: €0.90The company is up 10.0% from its price of €0.82 on 05 August 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 11% over the same period.
Reported Earnings • Sep 28First half earnings releasedOver the last 12 months the company has reported total losses of €827.0k, with earnings decreasing by €1.35m from the prior year. Total revenue was €51.2m over the last 12 months, down 1.9% from the prior year.